About the Company
neubase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. neubase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. neubase plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on huntington's disease and myotonic dystrophy, and dominant genetic disorders.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NBSE News
NeuBase Therapeutics board approves plan to dissolve company
NeuBase Therapeutics Inc.’s board of directors voted Thursday to dissolve and liquidate the Pittsburgh-based biotech firm, according to a document filed Friday with the U.S. Securities and ...
NeuBase Therapeutics (NASDAQ: NBSE)
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary ...
Biotech Stock News Bite - Elicio Therapeutics, Inc. (Nasdaq: ELTX) Rises on Funding News
Investorideas.com ( Biotech Stock News Bites - Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology ...
NeuBase Therapeutics Inc (O7P.SG)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Viking Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Buy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansion
Begin your TipRanks Premium journey today. Bioxcel Therapeutics (BTAI) Company Description: BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The ...
NeuBase Therapeutics Inc
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary ...
NeuBase Therapeutics Inc NBSE
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
NeuBase Therapeutics, Inc. (NBSE)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
NeuBase Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...